Circulatory neutrophil chemokines in statin-treated diabetic patients

Saudi Medical Journal

Volumn 29, Issue 4, 2008, Pages 584-588

  Alfadda, Assim A ^a   Alzoghaibi, Mohammed A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; ATORVASTATIN; CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; SIMVASTATIN; CXCL1 CHEMOKINE; MICROTUBULE ASSOCIATED PROTEIN; TUBGCP2 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIET THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH REGULATED ONCOGENE ALPHA; HUMAN; MALE; MONOTHERAPY; NEUTROPHIL; SAUDI ARABIA; UNIVERSITY HOSPITAL; BLOOD; CHEMISTRY; MIDDLE AGED;

CHEMOKINE CXCL1; CHEMOKINE CXCL5; CHEMOKINES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEUTROPHILS;

EID: 46749129447     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Crook MA, Tutt P, Pickup JC. Elevated serum sialic acid concentration in NIDDM and its relationship to blood pressure and retinopathy. Diabetes Care 1993; 16: 57-60.
2. Festa A, D'Agostino R Jr., Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
3. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248.
4. Libby P. Atherosclerosis: The new view. Sci Am 2002; 286: 46-55.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
6. Tuttle HA, Davis-Gorman G, Goldman S, Copeland JG, McDonagh PF. Proinflammatory cytokines are increased in type 2 diabetic women with cardiovascular disease. J Diabetes Complications 2004; 18: 343-351.
7. Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984; 26: 373-412.
8. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
9. Chen D, Assad-Kottner C, Orrego C, Torre-Amione G. Cytokines and acute heart failure. Crit Care Med 2008; 36 (Suppl 1): S9-S16.
10. Lindley IJ. Interleukin-8. In: Mire-Sluis AR, Thorpe R, editors. Cytokines. New York (NY): Academic Press Limited; 1998. p. 225-240.
11. Wuyts A, Proost P. Interleukin-8 and other CXC chemokines. In: Thomson A, editor. The Cytokine Handbook. San Diego (CA): Academic Press Limited; 1998. p. 272-302.
12. Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes-associated macrovasculopathy: Pathophysiology and pathogenesis. Diabetes Obes Metab 2007; 9: 767-780.
13. Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003; 52: 1256-1264.
14. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation 2002; 106: 2067-2072.
15. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53: 2079-2086.
16. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992; 130: 43-52.
17. Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 2001; 24: 956-957.
18. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993; 268: 26055-26058.
19. Hotamisligil GS. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621-625.
20. McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: Down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 1999; 52: 465-477.
21. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation 2004; 110: 886-892.
22. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
23. Zozulinska DA, Wierusz-Wysocka B, Wysocki H, Majchrzak AE, Wykretowicz A. The influence of insulin-dependent diabetes mellitus (IDDM) duration on superoxide anion and hydrogen peroxide production by polymorphonuclear neutrophils. Diabetes Res Clin Pract 1996; 33: 139-144.
24. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-376.
25. Wierusz-Wysocka B, Wysocki H, Siekierka H, Wykretowicz A, Szczepanik A, Klimas R. Evidence of polymorphonuclear neutrophils (PMN) activation in patients with insulin-dependent diabetes mellitus. J Leukoc Biol 1987; 42: 519-523.
26. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
27. Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2003; 2: 2.
28. Zozulinska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B. Serum interleukin-8 level is increased in diabetic patients. Diabetologia 1999; 42: 117-118.
29. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 2001; 15: 257-259.
30. Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N, et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 2002; 16:163-170.
31. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004; 5: 81-87.
32. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-135.
33. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007; 99: 732-738.
34. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev 2007; 65: 152-156.
35. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 2003; 88: 1055-1058.
36. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52: 942-947.
37. Bruun JM, Verdich C, Toubro S, Astrup A, Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol 2003; 148: 535-542.
38. Rehman J, Considine RV, Bovenkerk JE, Li J, Slavens CA, Jones RM, et al. Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol 2003; 41: 1408-1413.
39. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: 745-751.
40. Straczkowski M, Dzienis-Straczkowska S, Stepien A, Kowalska I, Szelachowska M, Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 2002; 87: 4602-4606.
41. Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H, Winkler H, et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 2007; 92: 4569-4574.